156 related articles for article (PubMed ID: 21208651)
21. Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells.
van Oosterwijk JG; van Ruler MA; Briaire-de Bruijn IH; Herpers B; Gelderblom H; van de Water B; Bovée JV
Br J Cancer; 2013 Sep; 109(5):1214-22. PubMed ID: 23922104
[TBL] [Abstract][Full Text] [Related]
22. Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft.
Glaser G; Weroha SJ; Becker MA; Hou X; Enderica-Gonzalez S; Harrington SC; Haluska P
PLoS One; 2015; 10(5):e0126867. PubMed ID: 25962155
[TBL] [Abstract][Full Text] [Related]
23. [Induction effect of rapamycin combined paclitaxel on apoptosis of ovarian cancer cell lines A2780 and SKOV3 and the molecular mechanism].
Ma XY; Wang SX; Liu Y; Liu RH; Lu YP; Ma D
Ai Zheng; 2007 Apr; 26(4):367-70. PubMed ID: 17430653
[TBL] [Abstract][Full Text] [Related]
24. Studies on combinations of platinum with paclitaxel and colchicine in ovarian cancer cell lines.
Yunos NM; Beale P; Yu JQ; Strain D; Huq F
Anticancer Res; 2010 Oct; 30(10):4025-37. PubMed ID: 21036717
[TBL] [Abstract][Full Text] [Related]
25. Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers.
Moisan F; Francisco EB; Brozovic A; Duran GE; Wang YC; Chaturvedi S; Seetharam S; Snyder LA; Doshi P; Sikic BI
Mol Oncol; 2014 Oct; 8(7):1231-9. PubMed ID: 24816187
[TBL] [Abstract][Full Text] [Related]
26. Dasatinib induces autophagic cell death in human ovarian cancer.
Le XF; Mao W; Lu Z; Carter BZ; Bast RC
Cancer; 2010 Nov; 116(21):4980-90. PubMed ID: 20629079
[TBL] [Abstract][Full Text] [Related]
27. Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Ovarian Cancer Cells
Kuittinen T; Rovio P; Luukkaala T; Laurila M; Grénman S; Kallioniemi A; Mäenpää J
Anticancer Res; 2020 Jun; 40(6):3129-3138. PubMed ID: 32487607
[TBL] [Abstract][Full Text] [Related]
28. Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib.
Serrels A; Macpherson IR; Evans TR; Lee FY; Clark EA; Sansom OJ; Ashton GH; Frame MC; Brunton VG
Mol Cancer Ther; 2006 Dec; 5(12):3014-22. PubMed ID: 17148760
[TBL] [Abstract][Full Text] [Related]
29. Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.
Eustace AJ; Crown J; Clynes M; O'Donovan N
J Transl Med; 2008 Sep; 6():53. PubMed ID: 18823558
[TBL] [Abstract][Full Text] [Related]
30. Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects.
Mundhenke C; Weigel MT; Sturner KH; Roesel F; Meinhold-Heerlein I; Bauerschlag DO; Schem C; Hilpert F; Jonat W; Maass N
J Cancer Res Clin Oncol; 2008 Dec; 134(12):1397-405. PubMed ID: 18465140
[TBL] [Abstract][Full Text] [Related]
31. S100P sensitizes ovarian cancer cells to carboplatin and paclitaxel in vitro.
Wang Q; He Z; Gao J; Hu S; Huang M; Liu M; Zheng J; Tang H
Cancer Lett; 2008 Dec; 272(2):277-84. PubMed ID: 18762368
[TBL] [Abstract][Full Text] [Related]
32. Effect of acetyl-l-carnitine on ovarian cancer cells' proliferation, nerve growth factor receptor (Trk-A and p75) expression, and the cytotoxic potential of paclitaxel and carboplatin.
Engle DB; Belisle JA; Gubbels JA; Petrie SE; Hutson PR; Kushner DM; Patankar MS
Gynecol Oncol; 2009 Mar; 112(3):631-6. PubMed ID: 19263582
[TBL] [Abstract][Full Text] [Related]
33. Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling.
Levitt JM; Yamashita H; Jian W; Lerner SP; Sonpavde G
Mol Cancer Ther; 2010 May; 9(5):1128-35. PubMed ID: 20406945
[TBL] [Abstract][Full Text] [Related]
34. Co-administration of NVP-AEW541 and dasatinib induces mitochondrial-mediated apoptosis through Bax activation in malignant human glioma cell lines.
Premkumar DR; Jane EP; Pollack IF
Int J Oncol; 2010 Sep; 37(3):633-43. PubMed ID: 20664932
[TBL] [Abstract][Full Text] [Related]
35. AS602801, an Anticancer Stem Cell Candidate Drug, Reduces Survivin Expression and Sensitizes A2780 Ovarian Cancer Stem Cells to Carboplatin and Paclitaxel.
Yamamoto M; Suzuki S; Togashi K; Sanomachi T; Seino S; Kitanaka C; Okada M
Anticancer Res; 2018 Dec; 38(12):6699-6706. PubMed ID: 30504379
[TBL] [Abstract][Full Text] [Related]
36. Dasatinib can enhance paclitaxel and gemcitabine inhibitory activity in human pancreatic cancer cells.
Ma L; Wei J; Su GH; Lin J
Cancer Biol Ther; 2019; 20(6):855-865. PubMed ID: 30866697
[TBL] [Abstract][Full Text] [Related]
37. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs.
Tomek S; Horak P; Pribill I; Haller G; Rössler M; Zielinski CC; Pils D; Krainer M
Gynecol Oncol; 2004 Jul; 94(1):107-14. PubMed ID: 15262127
[TBL] [Abstract][Full Text] [Related]
38. [Effect of estrogen or progesterone combined with paclitaxel on human ovarian cancer cell growth and Drosha expression].
Yang Y; Han K; Xie Y
Zhonghua Zhong Liu Za Zhi; 2015 Aug; 37(8):578-84. PubMed ID: 26714597
[TBL] [Abstract][Full Text] [Related]
39. Dasatinib attenuates overexpression of Src signaling induced by the combination treatment of veliparib plus carboplatin in triple-negative breast cancer.
Sun Y; Lin X; Aske JC; Ye P; Williams C; Abramovitz M; Leyland-Jones BR
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1241-1256. PubMed ID: 31541266
[TBL] [Abstract][Full Text] [Related]
40. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
Luo FR; Barrett YC; Yang Z; Camuso A; McGlinchey K; Wen ML; Smykla R; Fager K; Wild R; Palme H; Galbraith S; Blackwood-Chirchir A; Lee FY
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1065-74. PubMed ID: 18301894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]